Strong sales of cancer drugs and biopharmaceuticals helped push up revenues at AstraZeneca by 10 per cent in the first quarter, as the drugmaker said it would deepen its manufacturing presence in the US.
The Anglo-Swedish pharmaceutical group on Tuesday reported revenue of $13.6bn in the first three months of the year, up 10 per cent year on year in constant currencies, and declared it was “firmly committed to investing and growing in the US” as the sector braces for the fallout of Donald Trump’s trade war.
Chief executive Pascal Soriot said the FTSE 100 group continued to benefit from its “broad-based source of revenue and global manufacturing footprint”, adding it was planning “even greater” investment beyond its 11 US production sites.
您已閱讀21%（746字），剩餘79%（2770字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。